Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

CorVision® 4-year Follow-up (CorVision4yFU)

28 de maio de 2026 atualizado por: Katerina Klimesova, Gemini Eye Clinic

Four Years Extended Follow-Up on CorVision® Bioengineered Corneal Microlens: Safety and Efficacy

The objective of the study is to assess the long-term safety and effectiveness of the CorVision® microlens implanted in presbyopic patients for the management of management of presbyopia and near vision impairment. Approximately 100 patients in the Czech Republic will participate in this study. The study was reviewed and approved by an independent research ethics committee and also by the State Institute for Drug Control (SÚKL). The study will consist of a single visit during which standard, non-invasive, and painless examinations will be performed. This visit will correspond to the 4-year follow-up visit of the original clinical trial.

Visão geral do estudo

Status

Concluído

Condições

Tipo de estudo

Observacional

Inscrição (Real)

95

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Zlín, Tcheca, 760 01
        • Gemini Eye Clinic

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Método de amostragem

Amostra Não Probabilística

População do estudo

The target population are patients who suffered from presbyopia and underwent the original CorVision clinical study are medically suitable to undertake the current clinical study investigation.

Descrição

Inclusion Criteria:

  • Subjects must have undergone implantation of CorVision microlens under study protocol CMG-PRT-002.
  • Provide informed consent
  • Willing to participate in the ophthalmological examinations

Exclusion Criteria:

  • Patients with severe ocular or general disorders that would prevent them from completed the visit.
  • Patients not being able to understand and give informed consent.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Post-presbyopia correction with unilaterally implanted microlens
Presbyopic patients who have undergone implantation of the CorVision microlens according to study protocol CMG-PRT-002.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Uncorrected Near Visual Acuity of 0.3 logMAR or better
Prazo: At least 4 years after the implantation
More than 65% of the eyes should have an Uncorrected Near Visual Acuity (UNVA) of 0.3 logMAR or better at 4 years postoperatively.
At least 4 years after the implantation
Implant removal
Prazo: At least 4 years after the implantation
The incidence of implant rejection leading to implant removal should occur in no more than 3% of implanted eyes.
At least 4 years after the implantation

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Clinically significant corneal haze occurrence
Prazo: At least 4 years after the implantation
Clinically significant corneal haze is defined as any new stromal clouding in or near the laser-created pocket that leads to a reduction in central corneal clarity/transparency, is visible upon slit-lamp examination, and is graded as ≥ 2 on a standardized corneal haze grading scale.
At least 4 years after the implantation

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Monocular Uncorrected Near Visual Acuity at Best Reading Distance
Prazo: At least 4 years after the implantation
Change in monocular uncorrected near visual acuity and best reading distance over time
At least 4 years after the implantation
Monocular and Binocular Uncorrected Near Visual Acuity at 40 cm
Prazo: At least 4 years after the implantation
Change in monocular and binocular Uncorrected Near Visual Acuity (UNVA) at 40 cm.
At least 4 years after the implantation
Monocular and Binocular Distance Corrected Near Visual Acuity
Prazo: At least 4 years after the implantation
Change in monocular and binocular Distance Corrected Near Visual Acuity (DCNVA).
At least 4 years after the implantation
Monocular and Binocular Corrected Near Visual Acuity
Prazo: At least 4 years after the implantation
Change in monocular and binocular Corrected Near Visual Acuity (CNVA) over time.
At least 4 years after the implantation
Monocular and Binocular Uncorrected Intermediate Visual Acuity (UIVA)
Prazo: At least 4 years after the implantation
Change in monocular and binocular Uncorrected Intermediate Visual Acuity (UIVA) over time.
At least 4 years after the implantation
Monocular and Binocular Distance Corrected Intermediate Visual Acuity
Prazo: At least 4 years after the implantation
Change in monocular and binocular Distance Corrected Intermediate Visual Acuity (DCIVA) over time.
At least 4 years after the implantation
Monocular and Binocular Uncorrected Distance Visual Acuity (UDVA)
Prazo: At least 4 years after the implantation
Change in monocular Uncorrected Distance Visual Acuity (UDVA) over time.
At least 4 years after the implantation
Monocular and Binocular Corrected Distance Visual Acuity (CDVA)
Prazo: At least 4 years after the implantation
Change in monocular and binocular Corrected Distance Visual Acuity (CDVA) over time.
At least 4 years after the implantation
Objective refraction
Prazo: At least 4 years after the implantation
Change in objective refractive sphere and cylinder magnitude measured by autorefractometry.
At least 4 years after the implantation
Subjective refraction
Prazo: At least 4 years after the implantation
Change in manifest refractive sphere and cylinder magnitude, measured in diopters (D).
At least 4 years after the implantation
Near addition
Prazo: At least 4 years after the implantation
Change in near addition values over time.
At least 4 years after the implantation
Corneal Keratometry Measurements (K1, K2, and Kmean)
Prazo: At least 4 years after the implantation

Change in corneal keratometry values, including K1, K2, and mean keratometry (Kmean), as measured by corneal topography over time.

Change in keratometry K1, K2 and Kmean measured in diopters over time.

At least 4 years after the implantation
Central Corneal Thickness (Pachymetry) Measurement
Prazo: At least 4 years after the implantation
Change in central corneal thickness as measured by corneal pachymetry over time.
At least 4 years after the implantation
Endothelial Cell Density (Study Eye)
Prazo: At least 4 years after the implantation
Change in endothelial cell density over time.
At least 4 years after the implantation
Intraocular Pressure (Study Eye)
Prazo: At least 4 years after the implantation
Change in intraocular pressure over time.
At least 4 years after the implantation
Tear Film Break-Up Time (TBUT) Test
Prazo: At least 4 years after the implantation
Change in tear film stability as measured by Tear Film Break-Up Time (TBUT) in units of seconds.
At least 4 years after the implantation
Tear Production (Schirmer Test)
Prazo: At least 4 years after the implantation
Change in tear production as measured by the Schirmer test in units of mm.
At least 4 years after the implantation
Corneal Thickness Measurement Using Optical Coherence Tomography (OCT)
Prazo: At least 4 years after the implantation
Change in corneal thickness measured at the corneal center in μm.
At least 4 years after the implantation
Abnormal findings at OCT
Prazo: At least 4 years after the implantation
Incidence of abnormal findings on OCT.
At least 4 years after the implantation
Slit-lamp findings
Prazo: At least 4 years after the implantation
Incidence of abnormal slit lamp findings (eyelid, conjunctiva, epithelium, stroma, central cornea clarity, cornea neovascularization, anterior chamber, iris, lens).
At least 4 years after the implantation
Contrast sensitivity
Prazo: At least 4 years after the implantation
Determination of contrast sensitivity measured by CSV 1000 (Vector Vision) (changes from the pre-operative to the post-operative state and its stability over time will be investigated).
At least 4 years after the implantation
Defocus curve
Prazo: At least 4 years after the implantation
Change in visual acuity measured at different defocus vergence levels during monocular defocus curve testing over time.
At least 4 years after the implantation
Aberrometry measurements using iTrace
Prazo: At least 4 years after the implantation
Change in the total higher order aberrations (HOA) assessed by iTrace.
At least 4 years after the implantation
Subjective questionnaire QoV - patient satisfaction
Prazo: At least 4 years after the implantation
Evaluation of patient satisfaction assessed on a scale
At least 4 years after the implantation
Subjective questionnaire QoV
Prazo: At least 4 years after the implantation
Evaluation of patient satisfaction as assessed using the Quality of Vision (QoV) questionnaire scoring scale.
At least 4 years after the implantation
Adverse events incidence
Prazo: At least 4 years after the implantation
Intraoperative and adverse events at each time point (numbers and percentages)
At least 4 years after the implantation

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de junho de 2025

Conclusão Primária (Real)

25 de novembro de 2025

Conclusão do estudo (Real)

25 de novembro de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

15 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de maio de 2026

Primeira postagem (Real)

3 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de maio de 2026

Última verificação

1 de maio de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • CMG-PRT-002-1

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever